replacement was 32 months. Mean total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were 4.53 mmol/l (175 mg/dl) and 2.57 mmol/l (99 mg/dl), respectively. Conclusion: Results from the AURORA trial will impact on the current guidelines and use of statins in this patient population.
Introduction
End-stage renal disease (ESRD) is the most advanced manifestation of chronic kidney disease (CKD) . As the population ages and prevalence rates of type 2 diabetes increase, ESRD is set to be an increasing global problem. Worldwide, there are over 1 million patients with ESRD requiring dialysis, with an incidence of about a quarter of a million new patients each year [1] . Patients with ESRD have higher rates of hospitalisation than individuals without the disease [2, 3] . In the USA, treating patients with ESRD costs approximately USD 18 billion (6.6% of the Medicare budget) [3] . Cardiovascular disease (CVD) is highly prevalent in patients with ESRD and it is the single largest cause of premature mortality in this patient group [4] [5] [6] [7] . Controlling CVD risk factors in patients with ESRD has the potential to lower associated morbidity and mortality, and to thereby decrease the substantial burden on healthcare professionals and providers.
Several landmark trials have established the beneficial effect of statins (hydroxy-methylglutaryl-coenzyme A reductase inhibitors) in reducing cardiovascular morbidity and mortality [8] [9] [10] [11] [12] [13] [14] [15] [16] . Reductions in cardiovascular events have also been observed in patients treated with statins, but who do not have elevated cholesterol levels [13, 15, 16] . In addition, in the Heart Protection Study, the benefit of statin treatment was shown to be independent of baseline cholesterol levels [13] .
Most patients on haemodialysis do not have elevated total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) levels but they have other atherogenic lipid abnormalities, including low high-density lipoprotein cholesterol (HDL-C), elevated triglycerides (TG) and a higher proportion of intermediate and small, dense LDL particles [17] [18] [19] . In addition, oxidative stress, endothelial dysfunction and inflammation are all associated with decreasing renal function and dialysis in patients with ESRD [20] [21] [22] [23] , conditions that can help to promote atherosclerotic disease. As well as lowering LDL-C levels, statins have beneficial effects on other lipid parameters and have other (pleiotropic) effects, including anti-oxidant effects, improving endothelial dysfunction and lowering levels of C-reactive protein (CRP) [24] [25] [26] .
Patients with ESRD have usually been excluded from outcome studies of statins because of their related comorbidities and issues over safety and pharmacokinetics, leading to a scarcity of clinical characteristics and outcome data for these patients. Moreover, very little comprehensive global prospective data of this kind is available for patients with ESRD undergoing chronic haemodialysis. However, observational data indicate that statin treatment may improve survival in patients with ESRD [27] and large-scale randomised studies with statins in this patient group are required to confirm these findings [28] .
In Die Deutsche Diabetes Dialyse Studie (4D study), the effect of atorvastatin 20 mg compared with placebo on cardiovascular outcomes was assessed in 1,255 patients with type 2 diabetes receiving haemodialysis [29] . Atorvastatin did not significantly lower the incidence of the composite primary endpoint (death from cardiac causes, non-fatal myocardial infarction [MI] , or fatal or non-fatal stroke), although there were fewer events in the atorvastatin group (226 vs. 243 in the placebo group; relative risk [RR] 0.92, 95% confidence intervals [CI] 0.77-1.10; p = 0.37). Cases of fatal stroke occurred significantly more frequently in the atorvastatin group compared with the placebo group (RR 2.03, 95% CI 1.05-3.93; p = 0.04), contributing to the finding that the treatment effect on the primary endpoint was less than predicted. Atorvastatin reduced the rate of all cardiac events combined, compared with the placebo group (RR 0.82, 95% CI 0.68-0.99; p = 0.03).
There is a clear need for further long-term studies of patients with ESRD to clarify the role of statins on cardiovascular outcomes. Rosuvastatin is the most effective of the available statins for lowering LDL-C levels, as well as having benefits across the lipid profile [30, 31] . These properties make it an ideal agent for a study to investigate the benefits of statin treatment for the prevention of cardiovascular events in a population of patients at high risk of these events.
AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events) is the first large-scale international trial to assess the effects of a statin on cardiovascular morbidity and mortality in patients with ESRD on chronic haemodialysis, irrespective of baseline lipid levels. This report presents preliminary baseline data for patients randomised into the study.
Methods
Detailed methodology and the rationale for the AURORA study have been published previously [32] .
Study Design
AURORA is a randomised, double-blind, multicentre, parallel-group, international, phase IIIb study ( fig. 1 ). Patients have been randomised into the study from 280 centres in 25 countries ( table 1 ). They have been randomised (1: 1) to receive either rosuvastatin 10 mg or placebo and are being assessed at regular intervals during the study.
The study is being conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Conference of Harmonisation Good Clinical Practice guidelines and local regulatory requirements. All randomised patients provided written informed consent.
Patients
Men and women aged 50-80 years with ESRD and receiving regular chronic haemodialysis (inclusive of haemofiltration and haemodiafiltration) for at least 3 months were screened for eligibility.
Major exclusion criteria included the likely requirement for kidney transplantation within 1 year; major haematological, neoplastic, metabolic (excluding diabetes), gastrointestinal or infectious disease that may reduce survival to ! 1 year; history of malignancy; statin therapy within the previous 6 months; active liver disease (alanine aminotransferase 1 3 ! the upper limit of normal [ULN]); uncontrolled hypothyroidism (thyroid-stimulating hormone 1 1.5 ! ULN); and unexplained creatine kinase 1 3 ! ULN.
Endpoints
The efficacy endpoints will be analysed using the intentionto-treat population, which includes all randomised patients. Details of specific statistical analyses have been described previously [32] .
The primary endpoint is the time to a major cardiovascular event (cardiovascular death, non-fatal MI or non-fatal stroke). All deaths, MIs and strokes are being reviewed and adjudicated by a Clinical Endpoint Committee (in a blinded manner) to ensure consistency of event diagnosis.
Secondary endpoints include all-cause mortality, cardiovascular event-free survival (cardiovascular death, non-fatal MI, non-fatal stroke or death from any other cause), cardiovascular death, noncardiovascular death, procedures as a result of stenosis or thrombosis of the vascular access for chronic haemodialysis (arteriovenous fistulas and grafts only), and coronary or peripheral revascularisations. In addition, the health economic impact of rosuvastatin treatment will be analysed.
In subsequent studies and pre-specified subgroup analyses, the assessment of the prognostic value of various blood markers (CRP, lipid parameters, parathormone, vitamin D 3 , calcium phosphate product, asymmetrical dimethylarginine [ADMA], B-type natruiretic peptide [BNP], pregnancy-associated plasma protein A [PAPP-A], cardiotrophins and collagen parameters) and the potential interaction with rosuvastatin is planned. A sub-study on telomere length is also intended. Furthermore, the effect of mean systolic and diastolic blood pressure, and pulse pressure on the primary and secondary variables will be performed in detail, with specific consideration of the potential impact of rosuvastatin.
Statistical Analysis
The statistical methodology has been published previously [32] .
The Executive Steering Committee recently re-evaluated the underlying assumptions of the AURORA study in the light of recently reported studies in similar populations, particularly the 4D [29] and Assessment of LEscol in Renal Transplantation (ALERT) trials [33] . Although these studies observed a substantial reduction in the risk of MI with lipid-lowering therapy, no reduction was observed on stroke. This may indicate the presence of a nonmodifiable endpoint in the composite primary endpoints of these studies. Therefore, the Executive Steering Committee recommended an assumption of a neutral (0%) treatment effect on strokes and that the assumed placebo annual event rate should be adjusted in line with the observed annual event rate and the revised overall expected treatment effect. These changes were also endorsed by the full Steering Committee.
These modifications were considered scientifically reasonable and necessary given the importance of the study to the medical community. The independent Data and Safety Monitoring Board (DSMB) supported these recommendations and the protocol was consequently amended, thus extending the study by an expected 7 months.
The revised sample size was therefore based upon an assumed cardiovascular event rate of 12% per year in the placebo group. To detect a 19.5% reduction in cardiovascular event rate per year at a two-sided significance level of 4.719% (5% level adjusted for the interim analysis), with 87% power, the study should continue until approximately 805 patients have experienced a major cardiovascular event. This is expected to be 4.6 years after initiation of the study, which began in January 2003.
Interim Analysis
The DSMB performed an interim analysis when 305 patients had experienced a major cardiovascular event, as specified in the original protocol. All endpoints that occurred before or on March 17, 2005 were included in the analysis. The purpose was to investigate the possibility of concluding a significant difference between treatments for the time from randomisation to a major cardiovascular event. Following the interim analysis, the DSMB recommended to the Steering Committee and the study sponsor for the study to continue as planned.
Results
The AURORA study began in January 2003 and the last patient was randomised in December 2004. From approximately 3,020 patients who entered the screening period, 2,775 patients were randomised into the study from 25 countries in Europe, the Americas and Australasia ( table 1 ) .
Baseline characteristics of the patient population are shown in tables 2-4 and figure 2 . Male patients comprised 62% of the population studied, and most patients were white. Mean age of the study population was 64 years, with patients aged between 50-59, 60-69 and 70-80 years equally represented. Mean body mass index (BMI) was 25 kg/m 2 , with 301 (11%) patients ! 20 kg/m 2 and 430 (15.5%) patients 6 30 kg/m 2 . Fifteen percent of patients were smokers. Mean systolic and diastolic blood pressure was 137 and 76 mm Hg, respectively ( table 2 ) . The median time since commencing renal replacement therapy was 32 months with just under half (47%) of all patients on therapy for ! 2.5 years. A total of 2,547 (92%) patients were receiving standard haemodialysis and 228 (8%) patients were receiving haemofiltration/haemodiafiltration; the most common type of access was by arteriovenous fistula (79% patients). Most patients (75%) were spending from 10 to 14 h per week on dialysis ( table 3 ) .
Just over half (51%) of the patients had a history of documented CVD or CVD risk equivalent, with diabetes, angina and peripheral arterial disease recorded most frequently (26, 19 and 15%, respectively) ( fig. 2 ) .
Baseline laboratory parameters are shown in table 4 . Mean TC and LDL-C levels were 4.53 mmol/l (175 mg/ dl) and 2.57 mmol/l (99 mg/dl), respectively, and mean HDL-C and TG levels were 1.16 mmol/l (45 mg/dl) and 1.75 mmol/l (155 mg/dl), respectively. Mean haemoglobin and haematocrit levels were within the target range recommended by international guidelines for patients with CKD [35, 36] .
Discussion
AURORA is the first large-scale prospective international trial to assess the effects of a statin on cardiovascular morbidity and mortality in ESRD patients on chronic haemodialysis, irrespective of baseline lipid levels. It will provide the largest database of its kind, with structured, prospective data collection and all primary endpoints being adjudicated by a Clinical Endpoint Committee. AURORA has the potential to provide a representative picture of the effect of statin therapy on cardiovascular morbidity and mortality in patients on chronic haemodialysis. Documented CVD and/or diabetes were present in half of the patients. The main lipid parameters at baseline were close to those observed in other studies of haemodialysis populations [19, 37, 38] , although they did appear to differ from those reported in the 4D study: Mean 8 SD baseline lipid levels in 4D: TC 220 8 42 mg/dl in placebo and 218 8 43 mg/dl in atorvastatin patients, LDL-C 127 8 30 mg/dl in placebo and 125 8 29 mg/dl in atorvastatin patients and TG 267 8 168 mg/dl in placebo and 261 8 165 mg/dl in atorvastatin patients -all higher lev- RRT = Renal replacement therapy; Kt/V = dialysis adequacy calculated from pre-and post-urea results [34] . els than in the AURORA patients at baseline; HDL-C was 36 8 14 mg/dl in placebo and 36 8 13 mg/dl in atorvastatin patients -lower than in AURORA patients at baseline [29, 39] . The difference in lipids at baseline between 4D and AURORA may be due to differing inclusion criteria: 4D only randomised patients with type 2 diabetes and excluded patients with fasting serum LDL-C levels of less than 80 mg/dl (2.1 mmol/l) or more than 190 mg/dl (4.9 mmol/l), whereas AURORA did not specify LDL-C levels or a history of diabetes in its inclusion criteria.
Mean baseline oxidised LDL levels (34.2 U/l) in AU-RORA were below levels previously observed in apparently healthy, middle-aged men from the general population (93 U/l) [40] . Diepeveen et al. [41] also report mean oxidised LDL levels in dialysis patients to be below those expected for the general population (42 U/l at baseline in the placebo arm), and they indicated that this may reflect the lower lipid levels present in these patients (mean 8 SD), baseline LDL-C 2.7 8 0.8 mmol/l in the placebo arm), which are similar to the baseline LDL-C levels in AURORA.
Outcome trials of statins in patients with conditions related to the disease profile of those enrolled in the AU-RORA trial include 4D [29, 39] , ALERT [33] and SHARP (Study of Heart And Renal Protection [42] ).
Data from the 4D study indicate the absence of a significant beneficial effect of atorvastatin on cardiovascular outcomes in patients with diabetes receiving haemodialysis, although a significant reduction in cardiac events was observed (RR 0.82, 95% CI 0.68-0.99; p = 0.03). Cases of fatal stroke were observed more frequently in the atorvastatin group compared with the placebo group, although the number of these (27 [4%] and 13 [2%] of patients, respectively) was low. Atorvastatin significantly reduced the secondary endpoint of all cardiac events combined, compared with the placebo group (246 vs. 205 in the placebo group; RR 0.82, 95% CI 0.68-0.99; To convert mg/dl to mmol/l, multiply by 0.02586 for cholesterol and by 0.01129 for triglycerides. fig. 2 ) , whereas all patients in the 4D study had type 2 diabetes. Second, patients were eligible for AURORA irrespective of their lipid profile and mean lipid levels were markedly lower than in the 4D population ( table 5 ) . Third, there was no upper limit on the duration of haemodialysis for inclusion in AURORA whereas patients in 4D were required to have been receiving haemodialysis for less than 2 years (mean duration approximately 8 months). Fourth, AURORA randomised 2,775 patients from 25 different countries whereas 4D was conducted in fewer patients (1,255) from a single country (Germany). Fifth, the statin treatment in both studies differed. Statin treatment in AURORA is rosuvastatin 10 mg once daily and in 4D it was atorvastatin 20 mg once daily (both studies had a placebo arm). Finally, although the lower age limit for inclusion in AU-RORA was 50 years, the mean age (64.2 years; SD 8.7) was similar to that in the 4D study (65.7 years; SD 8.3), which recruited patients aged 6 18 years.
The ALERT trial assessed the effects of fluvastatin therapy in renal transplant recipients [33] , for whom cardiovascular risk is considerably decreased compared with patients with ERSD [4] . Although the 17% risk reduction (112 vs. 134 events) with fluvastatin versus placebo for the primary endpoint (occurrence of a major adverse cardiac event) was not significant, there were significantly fewer cardiac deaths or non-fatal MIs (35% risk reduction vs. placebo; 70 vs. 104 events, p ! 0.005). In both groups (fluvastatin and placebo), 15% had experienced a cardiac, cerebrovascular or other vascular event at baseline, which was lower than the predicted rate, leading to insufficient power to detect a significant reduction in the primary endpoint. In the ALERT extension study, patients receiving fluvastatin had a significant reduction in the relative risks of a major adverse cardiac event (risk reduction, 21%; 137 vs. 174 events; p = 0.036) and of a cardiac death or non-fatal MI (risk reduction 29%; 95 vs. 128 events; p = 0.014) compared with placebo [43] .
The ongoing SHARP study is investigating the effect of simvastatin and ezetimibe on the frequency of major cardiovascular events in ϳ 9,000 patients with CKD ( ϳ 3,000 on dialysis) who do not have established coronary heart disease [42] . The study commenced in July 2003 and is expected to complete in December 2010.
The effects of rosuvastatin 10 mg and atorvastatin 20 mg on a range of lipid levels in high-risk patients with hypercholesterolaemia were assessed in the PULSAR (Prospective study to evaluate the Utility of Low doses of the Statins Atorvastatin and Rosuvastatin) trial. Rosuvastatin was significantly more effective than atorvastatin at improving LDL-C levels (-45% vs. -43% mean change from baseline; p = 0.05) and HDL-C levels (6.4% vs. 3.1% mean change from baseline; p ! 0.001) in this patient group [44] .
The recently reported Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study assessed the effects of atorvastatin 80 mg on patients with no known coronary heart disease who had experienced a stroke or transient ischaemic attack (TIA) within 1-6 months of study entry. The study followed 4,731 patients over 5 years and found that atorvastatin reduced the overall incidence of both stroke (absolute reduction in risk 2.2%, p = 0.03) and cardiovascular events (absolute reduction in risk 3.5%, p = 0.002) compared with placebo, despite a small increase in the number of hemorrhagic strokes. Baseline TC, LDL-C and HDL-C lipid levels were higher and TG levels were lower in SPARCL patients compared with AURORA patients [45] . The specific effects on stroke that may occur in AURORA, although the AURORA study was not designed to elicit them, could help to understand the conflicting outcomes on stroke seen in the SPARCL and 4D studies.
Rosuvastatin is the most effective statin for lowering LDL-C [46] [47] [48] and, in AURORA, it is expected that LDL-C will be reduced to levels below those previously achieved in other statin outcomes studies, due to the low baseline values in this population.
In conclusion, preliminary baseline data from the AU-RORA study show a representative population of patients with ESRD receiving haemodialysis. The expected results from this study have the potential to show the effect of statin therapy in improving cardiovascular outcomes in patients with ESRD and will help guide the optimal management of this patient population.
